立克次氏體2點IgG免疫熒光玻片試劑盒

Rickettsia 2-Antigen MIF IgG kit

廣州健侖生物科技有限公司

主要用途：用于檢測人血清中的立克次氏體 2 點 IgG 抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細小病毒等病原微生物的 IFA、MIF、ELISA試劑。

立克次氏體2點IgG免疫熒光玻片試劑盒

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

這項研究發(fā)表于《PLoS ONE》雜志上，Kumar，以及合著者、MU獸醫(yī)醫(yī)學院的副教授杰弗里·布萊恩，使用稱為ODDHSL的細菌通訊分子用來治療在培養(yǎng)基中生長的人胰腺癌細胞。經(jīng)過治療后，人胰腺癌細胞停止繁殖，未能遷移并開始死亡。
“我們之所以使用胰腺癌細胞，是因為這些細胞是發(fā)生在人體內(nèi)zui強大的，侵襲性的以及難以殺滅的癌細胞，” Kumar說。“為了表明，這種分子不僅可以阻止癌細胞擴散，而且實際上也會導致它們死亡，這是非常令人興奮的。因為這個治療方法表明，其很有希望應用于像胰腺癌這種侵襲性的癌癥。我們相信它也可用于其他類型的癌細胞，以及我們實驗室正在其他類型的癌細胞中測試該治療方法。”
Kumar說，他研究的下一步是在動物和人體試驗發(fā)生前，尋找一個更有效的方式將該分子引入癌細胞中。
“現(xiàn)在，我們zui大的挑戰(zhàn)是，尋找一種有效的方式引入該分子，” Kumar說。“在這個時候，我們只能夠用這種分子在實驗室中治療癌細胞。現(xiàn)在，我們使用一個更好的方法來處理動物癌癥，看看這個治療是否真的有效。本研究的早期結果是有希望的。如果進一步的研究，包括動物實驗，都成功后，下一步是將這個方法應用于臨床試驗。”

The study, published in PLoS ONE, by Kumar and co-author Jeffrey Bryan, an associate professor at MU Veterinary Medical School, uses a bacterial communication molecule called ODDHSL to treat human pancreas that grows in culture cancer cell. After treatment, human pancreatic cancer cells stop multiplying, fail to migrate and begin to die.
"The reason we use pancreatic cancer is because these cells are the most powerful, aggressive and hard-to-kill cancer in the body," Kumar said. "It's very exciting to show that this molecule not only stops the spread of cancer cells but actually causes them to die, as this treatment shows promise for promising invasiveness like pancreatic cancer We believe it is also available for other types of cancer cells and our laboratory is testing the treatment in other types of cancer cells. "
Kumar said the next step in his research is to find a more effective way to introduce the molecule into cancer cells before animal and human trials occur.
"Now, our biggest challenge is to find an effective way to introduce that molecule," Kumar said. "At this point, we were only able to use this molecule to treat cancer cells in the laboratory, and now we use a better approach to treating animal cancers and see if the treatment is really effective. The early results of this study were Hopefully, if further research, including animal experiments, is successful, the next step is to apply the method to clinical trials. "